ArticleCancer immunology, immunotherapy : CII2022
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study.
Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Clinicopathological and prognostic value of tertiary lymphoid structures in lung cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Pooled it
- Prognostic and clinicopathological significance of tertiary lymphoid structure in non-small cell lung cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- The Emerging Role of Tertiary Lymphoid Structures as Predictive and Prognostic Biomarkers of Immunotherapy in Cancer.Cancer medicine · 2026Review
- Exploring the Pivotal Functions of Tertiary Lymphoid Structures in Cancer Prognosis and Immunotherapy Outcomes.Cancers · 2025Review
- Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma.BMC cancer · 2025Article
- From heterogeneity to prognosis: understanding the complexity of tertiary lymphoid structures in tumors.Molecular biology reports · 2025Review
- Metabolically activated and highly polyfunctional intratumoral VISTAMolecular cancer · 2025Article
- Prognostic Value of Tertiary Lymphoid Structures in Stage I Nonsmall Cell Lung Cancer: Does Location Matter?Clinical Medicine Insights. Oncology · 2025Article
- The pivotal role of tertiary lymphoid structures in the tumor immune microenvironment.Frontiers in oncology · 2025Review
- Dynamic monocyte changes as prognostic indicators in operable gastric cancer: a retrospective cohort analysis.Frontiers in oncology · 2025Article
- Dissecting Tertiary Lymphoid Structures in Cancer: Maturation, Localization and Density.Theranostics · 2025Review
- Tertiary lymphoid structures and their therapeutic implications in cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Single-cell and spatial transcriptomics analysis of non-small cell lung cancer.Nature communications · 2024Article
- Article
- Impact of lymph node dissection on the efficacy of immune checkpoint inhibitors in patients with postoperative recurrence of non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.BMC pulmonary medicine · 2024Article
- Review
- Density of tertiary lymphoid structures and their correlation with prognosis in non-small cell lung cancer.Frontiers in immunology · 2024Article
- Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe presence of tertiary lymphoid structure (TLS) in tumor tissues has been reported to be a factor associated with a good prognosis in several types of cancers. However, the relationship between TLS formation and peripheral blood findings remains unclear. The purposes of the study were to evaluate the effect of the presence of TLS on survival and determine the peripheral blood characteristics associated with TLS formation in non-small cell lung cancer (NSCLC) patients.
methodsA total of 147 consecutive NSCLC patients who underwent lung resection at Fukushima Medical University Hospital between 2013 and 2017 were enrolled. TLS expression was evaluated, and the relationships between clinical parameters and outcomes were analyzed. Peripheral blood mononuclear cells (PBMCs) were further analyzed by mass cytometry to characterize the TLS-positive microenvironment.
resultsForty-six patients had high TLS expression, and the remaining 101 patients had low TLS expression. In stage II to IV patients (n = 35), disease-free survival was longer in the high TLS expression group (p = 0.027). A low neutrophil to lymphocyte ratio (NLR) < 2.75 in the peripheral blood was associated with high TLS expression (p = 0.003). Citrus analysis after mass cytometry assay showed that the number of cells expressing HLA-DR and CD9 in PBMCs was lower in the high TLS expression group.
conclusionHigh TLS expression is associated with a good prognosis after surgery in stage II and III NSCLC patients. In the peripheral blood, a low NLR and few antigen-presenting cells indicate the presence of TLS in the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.